Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Free Access

The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment

Schulze T.G.a, g,ε · Alda M.m, ε · Adli M.h, ε · Akula N.a · Ardau R.t · Bui E.T.a · Chillotti C.t · Cichon S.i, ζ · Czerski P.v · Del Zompo M.t, u · Detera-Wadleigh S.D.a · Grof P.n, o, ε · Gruber O.j · Hashimoto R.x, δ · Hauser J.v · Hoban R.b, c · Iwata N.y, δ · Kassem L.a · Kato T.z, δ · Kittel-Schneider S.k · Kliwicki S.w · Kelsoe J.R.b, c · Kusumi I.β, δ · Laje G.a · Leckband S.G.b, d, e · Manchia M.u · MacQueen G.p · Masui T.β, δ · Ozaki N.γ, δ · Perlis R.H.f · Pfennig A.l, ε · Piccardi P.u · Richardson S.a · Rouleau G.q · Reif A.k · Rybakowski J.K.w, ε · Sasse J.l, ε · Schumacher J.a, i · Severino G.u · Smoller J.W.f · Squassina A.u · Turecki G.r · Young L.T.s, ε · Yoshikawa T.α, δ · Bauer M.l, ε · McMahon F.J.a

Author affiliations

aGenetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., bDepartment of Psychiatry, University of California San Diego, cDepartment of Psychiatry, VA San Diego Healthcare System, and dDepartment of Pharmacy, VA San Diego Healthcare System, La Jolla, Calif., eSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, Calif., and fDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Mass., USA; gDepartment of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, hDepartment of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, iDepartment of Genomics, Life and Brain Center and Institute of Human Genetics, University of Bonn, Bonn, jDepartment of Psychiatry and Psychotherapy, Georg-August University, Göttingen, kDepartment of Psychiatry, Psychosomatics, and Psychotherapy, University of Würzburg, Würzburg, and lDepartment of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; mDepartment of Psychiatry, Dalhousie University, Halifax, N.S., nMood Disorders Center of Ottawa, Ottawa, Ont., oDepartment of Psychiatry, University of Toronto, Toronto, Ont., pDepartment of Psychiatry, University of Calgary, Calgary, Alta., qCHU Sainte-Justine Research Center, Department of Medicine, University of Montreal, and rDepartment of Psychiatry, Douglas Hospital Research Institute, McGill University, Montreal, Que., and sDepartment of Psychiatry, University of British Columbia, Vancouver, B.C., Canada; tUnit of Clinical Pharmacology, Hospital University Agency, and uDepartment of Neuroscience ‘B.B. Brodie’, University of Cagliari, Cagliari, Italy; vPsychiatric Genetic Unit, and wDepartment of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland; wOsaka University Graduate School of Medicine, Osaka,yDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake,zLaboratory for Molecular Dynamics of Mental Disorders, andαLaboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama,βDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo,γDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan;δThe Japanese Collaborative Group on the Genetics of Lithium Response in Bipolar Disorder;εThe International Group for the Study of Lithium-Treated Patients (IGSLI);ζInstitute of Neurosciences and Medicine (INM-1), Research Center Juelich, Juelich, Germany

Corresponding Author

Thomas G. Schulze, MD, Unit on the Genetic Basis of Mood and Anxiety Disorders

National Institute of Mental Health (NIMH), National Institutes of Health (NIH)

35 Convent Drive, Bldg. 35, Rm 1A205, MSC 3719

Bethesda, MD 20892-3719 (USA)

Tel. +1 301 451 7213, Fax +1 301 402 9081, E-Mail schulzet@mail.nih.gov

Related Articles for ""

Neuropsychobiology 2010;62:72–78

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: May 08, 2010
Issue release date: June 2010

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 0

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: http://www.karger.com/NPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.